ASTRAZEN · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 54/100 — Quality 59 · Momentum 40
| Share price | ₹8,054.50 |
| Market cap | ₹22,122 Cr |
| P/E ratio | 109.9 |
| P/B ratio | 27.7 |
| ROE | 18.1% |
| ROCE | 19.4% |
| Dividend yield | 0.36% |
| Book value | ₹319.63 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2025 | ₹1,713 Cr | ₹116 Cr | 12.5% |
| 2024 | ₹1,296 Cr | ₹162 Cr | 13.2% |
| 2023 | ₹1,003 Cr | ₹99 Cr | 14.8% |
| 2022 | ₹806 Cr | ₹62 Cr | 8.6% |
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company was incorporated in 1979 and is based in Bengalur